Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Siemens Healthineers and Novo will collaborate to expand awareness and access to blood-based non-invasive tests for MASLD and MASH, aiming to reduce reliance on liver biopsy and support earlier triage. The effort highlights Siemens’ Enhanced Liver Fibrosis (ELF) test, a US-authorized blood test for progression risk in
Siemens Healthineers and Novo said they have agreed to work together to improve care for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).
Siemens Healthineers and Novo announced a collaboration aimed at advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).